ClinicalTrials.gg
RecruitingNCT06582225Updated Sep 14, 2026

ICBT for OCD in Children With Autism

An interventional study of Internet-delivered exposure and response prevention (I-ERP) and Internet-delivered stress management (I-SM) in Obsessive-Compulsive Disorder and Autism Spectrum Disorder, sponsored by Karolinska Institutet. Recruiting at 3 sites in Sweden. Open to participants aged 7 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
7 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Obsessive-Compulsive Disorder by Karolinska Institutet — 3 open to participants now, 3 under way, none of them phase 3. Obsessive-Compulsive Disorder · Karolinska Institutet.

Planned enrollment
Largest of 15
220 · median 83
Started
2024
the only one that year
No phase
13 of 17
3 open now
Registered
16th of 17
by date

Among the 17 studies in Obsessive-Compulsive Disorder by Karolinska Institutet, this one has the largest planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2024, is one of 13 with no phase, and was the 16th registered.

Obsessive-Compulsive Disorder

637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Open to participants now

3 of the 17 studies in Obsessive-Compulsive Disorder by Karolinska Institutet are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.

This study: 7 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Obsessive-Compulsive Disorder by Karolinska Institutet, or all of them as a file.
02

Study summary

The purpose of this trial is to evaluate the clinical efficacy, the cost-effectiveness and the effect durability of a therapist-guided, internet-delivered cognitive-behavior therapy intervention for obsessive-compulsive disorder (OCD) in children and adolescents with autism. A process evaluation of the treatment will also be conducted.

Read the detailed description

Primary objective: To determine the clinical efficacy of autism-adapted internet-delivered exposure with response prevention (I-ERP) in reducing OCD symptom severity (as measured by the Children's Yale Brown-Obsessive Compulsive Scale; CY-BOCS) in children and adolescents with OCD and autism spectrum disorder (ASD), compared with an active control intervention of high ecological validity (internet-delivered stress management; I-SM).

Secondary objectives:

  1. To establish the 6-month durability of the treatment effects in a naturalistic follow-up.
  2. To conduct a health economic evaluation of I-ERP, compared with I-SM, at the primary endpoint (3-month follow-up) from the health organisation payer, health care sector, and societal perspectives.
  3. To conduct a process evaluation with a subset of participants allocated to the I-ERP arm, focusing on implementation, mechanisms of impact, and context.

Type of trial: A multisite parallel-group randomised controlled superiority trial, with embedded health economic and process evaluation.

Rationale: OCD and ASD are two frequently co-occuring disorders, associated with significant impairments in daily life. Cognitive-behavioural therapy (CBT) specifically adapted to ASD is a promising treatment for this patient group, but further research is needed to fully establish its efficacy. Furthermore, ASD-adapted CBT for OCD is a highly specialised treatment, not accessible for most patients. Offering treatment in a digital format could dramatically increase treatment availability for these children.

Planned trial sites: The study will be coordinated from the Department of Clinical Neuroscience at Karolinska Institutet (the Sponsor). There will be three collaborating study sites: BUP OCD och relaterade tillstånd (Region Stockholm), BUP Specialmottagning (Västra Götalandsregionen), and BUP Skåne (Region Skåne). Each of the three sites will assess and treat participants from their own region, and occasionally from adjacent regions.

Trial design and methods: All potential participants are initially screened via the telephone or at one of the three participating centres. If screening is positive, an inclusion assessment will follow. Individuals who are eligible and have consented to participate in the trial will be randomised to one of two trial arms. In one arm, participants will receive 12 modules of therapist- and parent-guided I-ERP for OCD adapted for autism. In the active comparator arm, participants will receive 12 modules of therapist- and parent-guided I-SM. Participants in the comparator group will be offered to cross-over to the I-ERP intervention after the primary endpoint.

Participants will complete outcome measures at baseline (week 0), post-treatment (week 12), and 3- and 6-months post-treatment. The primary outcome variable is the clinician-reported Children's Yale Brown-Obsessive Compulsive Scale (CY-BOCS), and the primary endpoint is the 3-month follow-up after treatment.

Secondary outcomes include measures of self-reported OCD symptoms, family accommodation, functional impairment, and depressive symptoms. Health-related quality of life and resource use will be collected for the health economic evaluation. Follow-up assessments will be conducted at the clinic or via videoconferencing, in both cases complemented with online questionnaires.

A subset of participants will participate in a process evaluation of the I-ERP intervention.

Sample: A total of 220 autistic children and adolescents diagnosed with OCD and their primary caregivers.

Statistical methodology and analysis: Data will be analysed using a pre-specified intention-to-treat statistical analysis plan. The primary outcome will be analysed using a linear mixed effects model. Secondary outcomes will be analysed using analogous methods. A health economic evaluation of the intervention from the health organisation payer, health care sector, and societal perspectives will also be conducted, as well as a process evaluation including both quantitative and qualitative measures.

03

Conditions studied

  • Obsessive-Compulsive Disorder
  • Autism Spectrum Disorder

Keywords

  • Obsessive-Compulsive Disorder
  • Autism Spectrum Disorder
  • Exposure and Response Prevention
  • Cognitive-Behavioural Treatment
  • Internet
  • Guided self-help
  • Stress Management
04

Who can participate

Ages eligible
7 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A diagnosis of autism, based on the diagnostic criteria of the 4th or 5th edition of the (DSM) or the 10th edition of the International Classification of Diseases (ICD-10). Informed by the parent/caregiver and subsequently confirmed by review of the medical record or the neurodevelopmental assessment report. A diagnosis of autism will be considered present if it was established with validated instruments, such as the Autism Diagnostic Interview-Revised (ADI-R), the Autism Diagnostic Observation Schedule (ADOS) edition 1 or 2 or the Diagnostic Interview for Social and Communication Disorders (DISCO; autism or ASD cut-offs).
  2. A DSM-5 diagnosis of OCD. Confirmed by the assessor at the inclusion assessment, based on a structured diagnostic interview.
  3. A total score of ≥16 on the CY-BOCS. Confirmed by the assessor at the inclusion assessment.
  4. Age between 7 and 17 years. Confirmed by the caregiver and subsequently by the medical record system.
  5. Ability to read and write Swedish. Confirmed by the caregiver at the telephone screening or/and the inclusion assessment.
  6. Regular access to a computer or a smartphone/tablet connected to the internet, and a mobile phone to receive text messages. Confirmed by the caregiver at the telephone screening or/and inclusion assessment.
  7. A parent/caregiver able to participate in the treatment alongside their child. Confirmed by the caregiver at the telephone screening or/and the inclusion assessment.

Exclusion criteria

Exclusion Criteria:

  1. Global intellectual disability. Informed by the parent/caregiver and subsequently confirmed by review of the medical record or the neurodevelopmental assessment report, and additionally estimated with the two subtests matrix reasoning and similarities from the Wechsler Intelligence Scale for Children - fifth edition (WISC-V) or Wechsler Adult Intelligence Scale - fourth edition (WAIS-IV).
  2. Comorbid psychotic disorder, bipolar disorder, severe eating disorder, severe depression, alcohol/substance dependence or hoarding disorder. Confirmed by the caregiver at the telephone screening and subsequently by the assessor at the inclusion assessment based on the structured diagnostic interview and, if required, the medical record.
  3. Current suicidal intent or a previous suicide attempt within the last 12 months. Confirmed by the assessor at the inclusion assessment and, if required, the medical record.
  4. Main symptom presentation consists of hoarding symptoms. Confirmed by the assessor at the inclusion assessment.
  5. Completed CBT for OCD within the last 12 months prior to the inclusion assessment (defined as at least 5 sessions of CBT including ERP). Confirmed by the caregiver at the telephone screening or/and inclusion assessment and, if required, the medical record.
  6. Simultaneous psychological treatment for OCD or anxiety. Confirmed by the caregiver at the telephone screening and/or inclusion assessment.
  7. Initiation, dosage change or cessation of medication for OCD (primarily selective serotonin reuptake inhibitors, SSRIs) or behavioural symptoms of ASD (atypical antipsychotics) within the 6 weeks prior to the baseline assessment. Confirmed by the caregiver at the telephone screening and the inclusion assessment and, if required, the medical record.
  8. Having a close relationship to an already included participant (e.g., sibling, cousin), to avoid being randomised into two different arms, with the risk of information "leaking" between the groups. Confirmed by the caregiver or assessor at the telephone screening and/or at the inclusion assessment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Internet-delivered exposure and response prevention (I-ERP)

    A therapist-guided, internet-delivered exposure and response prevention (I-ERP) programme for children and adolescents with OCD and autism.

    Behavioral: Internet-delivered exposure and response prevention (I-ERP)

  • Active comparator
    Internet-delivered stress management (I-SM)

    A therapist-guided, internet-delivered stress management (I-SM) programme for children and adolescents with OCD and autism.

    Behavioral: Internet-delivered stress management (I-SM)

Interventions

  • BehavioralInternet-delivered exposure and response prevention (I-ERP)

    The intervention is internet-delivered and therapist-guided, involving the child and at least one caregiver. It consists of two separate sets of modules, one for the child and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks. The treatment includes psychoeducation about ASD, OCD, emotions, healthy habits, the difference between repetitive behaviours in autism and OCD, how compulsions maintain the obsessions, and the rationale for ERP. The main focus of the treatment is ERP tasks based on the young person's individual goals. The modules also contain homework tasks that are meant to be completed between modules, mainly consisting of ERP. The final module includes a summary of the treatment and a relapse prevention plan. The version for parents consists of the same content as the child treatment, but with elaborated psychoeducation, and additional focus on strategies on how to assist their child in the different exposure tasks.

  • BehavioralInternet-delivered stress management (I-SM)

    The intervention is internet-delivered and therapist-guided, involving the child and at least one caregiver. It consists of two separate sets of modules, one for the child and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks. The treatment includes psychoeducation about ASD, OCD, healthy habits, and how stress is a contributor to OCD symptoms. The rationale is that targeting and reducing stress will have a beneficial impact on anxiety, obsessions, and compulsions. The main goal of the treatment is to learn how to reduce stress, mainly by using relaxation techniques such as deep breathing, progressive muscle relaxation, and imagery (cognitive) relaxation. The modules also contain homework tasks that are meant to be completed between modules, mainly consisting of relaxation tasks. The version for parents contains psychoeducation, as well as strategies on how to assist their child in the different relaxation tasks.

06

What researchers measure

Primary outcomes

  1. Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS)

    The CY-BOCS is a semi-structured clinician-administered scale used to assess the severity of OCD symptoms in children and adolescents. The scale consists of a checklist of obsessions and compulsions, 10 items assessing the severity of the OCD symptoms, and a series of ancillary items (e.g., level of insight, avoidance). Range: 0-40, lower scores mean better outcome.

    Time frame: Baseline (week 0), post treatment (week 12), 3-months follow-up, 6-months follow up.

Secondary outcomes

  1. Clinical Global Impression - Severity (CGI-S)

    Used to provide an overall rating of the OCD severity. Clinician-rated. Range: 1-7, lower scores mean better outcome.

    Time frame: Baseline (week 0), post treatment (week 12), 3-months follow-up, 6-months follow up.

  2. Clinical Global Impression - Improvement (CGI-I)

    Used to assess global improvement. Clinician-rated. Range: 1-7, lower scores mean better outcome.

    Time frame: Post treatment (week 12), 3-months follow-up, 6-months follow up.

  3. Treatment response and remission

    Treatment response will be defined as at least 35% reduction on the CY-BOCS and a CGI-I score of 1 (very much improved) or 2 (much improved). Remission will be defined as a score of less than or equal to 12 on the CY-BOCS and a CGI-S rating of 1 (normal, not at all ill) or 2 (borderline mentally ill).

    Time frame: Post treatment (week 12), 3-months follow-up, 6-months follow up.

  4. Children's Global Assessment Scale (CGAS)

    The CGAS is a single item 1-100 scale that integrates psychological, social, and academic functioning in children as a measure of psychiatric disturbance. Higher scores mean better outcome. It will be used in this trial to provide an assessor-rated opinion of global improvement (not restricted to OCD symptoms).

    Time frame: Baseline (week 0), post treatment (week 12), 3-months follow-up, 6-months follow up.

  5. Obsessive-Compulsive Inventory - Child version - revised (OCI-CV-R)

    The OCI-CV-R is an 18-item self-reported measure of OCD symptoms. Each item is scored on a 3-point scale (0=never, 1=sometimes, 2=always). The OCI-CV-R generates a total score ranging from 0-36 points and five sub-scores (doubting/checking, obsessing, washing, ordering, and neutralizing), with higher scores indicating greater OCD symptom severity.

    Time frame: Baseline (week 0), during treatment (week 3, week 6, week 9), post treatment (week 12), 3-months follow-up, 6-months follow up.

  6. Children's Obsessive-Compulsive Inventory-Revised-Parent version (ChOCI-R-P)

    The ChOCI-R-P is a parent-rated measure of OCD symptom severity that includes a checklist and a severity rating with 12 items, yielding a total score of 0-48 with higher scores indicating greater OCD symptom severity.

    Time frame: Baseline (week 0), during treatment (week 3, week 6, week 9), post treatment (week 12), 3-months follow-up, 6-months follow up.

  7. Generalized Anxiety Disorder - 7 item scale (GAD-7)

    The GAD-7 is a measure of anxiety rated by the child/adolescent. It consists of 7 items and each item is rated from 0=not at all to 3=almost every day, yielding a total score of 0-21. Lower scores mean better outcome.

    Time frame: Baseline (week 0), post treatment (week 12), 3-months follow-up, 6-months follow up.

  8. Child Health Utility 9D (CHU9D)

    The CHU9D is a 9-item measure of quality of life rated by the child/adolescent. Each item is scored from 1 to 5, assessing children's functioning "today" across domains of worry, sadness, pain, tiredness, annoyance, school, sleep, daily routine and activities. Scores are converted to utility weights using a scoring algorithm. Weights range between 0 (denoting the health state "dead") and 1 (denoting the health state "perfect health"). Weights are then used to estimate quality adjusted life years (QALY) to be used in the health economic evaluation.

    Time frame: Baseline (week 0), post treatment (week 12), 3-months follow-up, 6-months follow up.

  9. Trimbos/iMTA Questionnaire for Costs associated with Psychiatric Illness (TiC-P)

    The TiC-P will be used to assess healthcare and societal resource use for the health economic evaluation. The questionnaire includes items on healthcare resource use (e.g., healthcare visits), supportive resources (e.g., private tutoring), medications, prescription-free drugs, school absenteeism, academic productivity loss, and parental productivity loss and is frequently used in health economic studies. The TiC-P version used in the study has been adapted by the research team for the use among young people and parents and used in previous trials. No scores as such are available for this measure. Parent rated.

    Time frame: Baseline (week 0), post treatment (week 12), 3-months follow-up, 6-months follow up.

  10. Patient Exposure/Relaxation Adherence Scale (PEAS/PRAS)

    The PEAS/PRAS is a self-rated 3-item measure of patient adherence to exposure with response prevention (PEAS) with 3 items rated from 0 to 6, yielding a total score of 0-18, where higher scores indicate greater adherence. For the current trial, the measure will be administered as a self- rated version in the I-ERP group. A corresponding version (PRAS) has been developed by the research team and will be administered to participants in the control group to assess adherence to I-SM intervention. The PEAS/PRAS is a 3-item measure of patient adherence to exposure and response prevention (PEAS) or relaxation training (PRAS). The PEAS/PRAS is one single measure but it is adapted to each of the two arms. The PEAS/PRAS has 3 items rated from 0 to 6, yielding a total score of 0-18. Higher scores mean better outcome. For the current trial, the PEAS will be administered as a self-rated version in the I-ERP group and the PRAS will be administered as a self-rated version in the I-SM group.

    Time frame: During treatment (week 3, week 6, week 9), post treatment (week 12), 3-months follow-up.

  11. Treatment preference

    Two items will be administered to both the participant and the parent to assess treatment format preference (i.e., if the participant/parent would have preferred to receive internet-delivered treatment or in-person treatment for his/her symptoms or if it does not matter), as well as how important the participant and parent believe it is to be able to choose which treatment format they receive (rated on a 5-point scale). The questionnaire has been developed by the research team.

    Time frame: Baseline (week 0), post treatment (week 12).

  12. Treatment Credibility and Expectancy Scale (TCES)

    The TCES will be administered to both the participant and the parent to assess the treatment credibility and expectancy of treatment outcome. The TCES includes 5 items rated from 0 to 10, yielding a total score of 0-40, where higher scores indicate higher credibility.

    Time frame: During treatment (week 3).

  13. Working alliance inventory (WAI)

    The WAI is a measure of perceived working alliance with the therapist that includes 6 items rated from 1=never to 7=always, yielding a total score of 7-49. It will be administered to both the participant and the parent. Higher scores mean better working alliance.

    Time frame: During treatment (week 3).

  14. Client Satisfaction Questionnaire (CSQ-8)

    The CSQ-8 is an 8-item measure of treatment satisfaction. Each item is rated from 1 to 4, yielding a total score of 9-36. Higher scores mean more satisfaction. It will be administered to both the participant and the parent.

    Time frame: Post treatment (week 12), 3-months follow-up.

  15. Family Accommodation Scale - self-rated (FAS-SR)

    The FAS-SR is a measure of family accommodation that includes 19 items about family accommodation. For the purpose of this trial, the checklist with obsessions and compulsions has been excluded, since it is not included in the total severity score and overlaps with the checklist in the ChOCI-R-P. Each item is rated from 0=none/never to 4=every day, yielding a total score of 0-76. Higher scores are associated with greater levels of family accommodation.

    Time frame: Baseline (week 0), post treatment (week 12), 3-months follow-up, 6-months follow up.

  16. Work and Social Adjustment Scale - youth (WSAS-Y)

    The WSAS-Y is a 5-item measure of functional impairment rated by the child/adolescent. Each item is rated from 0=not at all to 8=severely impaired, yielding a total score of 0-40. Lower scores mean better outcome.

    Time frame: Baseline (week 0), post treatment (week 12), 3-months follow-up, 6-months follow up.

  17. Work and Social Adjustment Scale - parent version (WSAS-P)

    The WSAS-P is a 5-item measure of functional impairment rated by the parent. Each item is rated from 0=not at all to 8=severely impaired, yielding a total score of 0-40. Lower scores mean better outcome.

    Time frame: Baseline (week 0), post treatment (week 12), 3-months follow-up, 6-months follow up.

  18. Short Mood and Feeling Questionnaire - child (SMFQ-C) + additional suicide item

    The SMFQ-C is a measure of depressive symptoms rated by the child/adolescent. It consists of 13 items and each item is scored on a 3-point scale (0=not true, 1=sometimes, 2=true). The total score is derived by adding up the values for each 13 items, yielding a total score of 0-26 points. Lower scores mean better outcome. For this trial, an item has been added aimed to assess suicide risk.

    Time frame: Baseline (week 0), during treatment (week 3, week 6, week 9), post treatment (week 12), 3-months follow-up, 6-months follow up.

  19. Short Mood and Feeling Questionnaire - parent version (SMFQ-P)

    The SMFQ-P is a measure of depressive symptoms rated by the parent. It consists of 13 items and each item is scored on a 3-point scale (0=not true, 1=sometimes, 2=true). The total score is derived by adding up the values for each 13 items, yielding a total score of 0-26 points. Lower scores mean better outcome.

    Time frame: Baseline (week 0), during treatment (week 3, week 6, week 9), post treatment (week 12), 3-months follow-up, 6-months follow up.

Other outcomes

  1. Demographic data - clinician-entered

    Following the inclusion assessment, the assessor enters baseline information into the trial database. This includes information on e.g., age, primary responsible caregiver assisting during the treatment, general cognitive ability, comorbid diagnoses, distance to the clinic in kilometres, age of OCD onset, history of suicide attempt, family history of OCD and ASD, family history of other psychiatric disorders, current medication for ASD, OCD or other psychiatric disorder, and previous psychological treatment for OCD or other psychiatric disorders.

    Time frame: Baseline (week 0).

  2. Demographic data - parent-reported

    At baseline, the parent/caregiver will answer a questionnaire designed by the research team asking about e.g., the caregiver's relation to the child, who the child lives with, the child's sex and gender, number of siblings, the caregivers' educational level, the caregivers' occupation, the country in which the child and caregivers were born, how the caregiver learned about the trial, and if the child has been in previous contact with health care services due to her/his OCD or other psychiatric symptoms.

    Time frame: Baseline (week 0).

  3. Comorbid psychiatric disorders

    Psychiatric diagnoses at baseline, including OCD, will be based on DSM-5 diagnostic criteria and assessed with the Diagnostic Interview for Anxiety, Mood, and OCD and Related Neuropsychiatric Disorders-Child and Adolescent Version (DIAMOND-KID).

    Time frame: Baseline (week 0).

  4. Social Communication Questionnaire (SCQ)

    The SCQ is a parent-rated measure of autistic symptoms that includes 40 items, yielding a total score of 0-40.

    Time frame: Baseline (week 0).

  5. IQ estimate

    Two subtests, matrix reasoning and similarities, from the WISC-V or WAIS-IV will be used to provide an estimate of full IQ.

    Time frame: Baseline (week 0).

  6. Concurrent interventions

    To assess what other treatments the child/adolescent is accessing during the trial period, the family is interviewed by the assessor at post-treatment and subsequent follow-ups. This includes questions about medications (type, dose, indication, and time period) and psychological treatment (type, number of sessions, indication, and time period).

    Time frame: Post treatment (week 12), 3-months follow-up, 6-months follow up.

  7. Adverse events

    A questionnaire will be administered to systematically assess adverse events at mid-treatment, post-treatment, 3-month follow-up, and 6-month follow-up. The questionnaire is developed by the research team and includes a checklist with expected adverse events based on previous trials as well as a free text box where other, not listed adverse events can be registered.

    Time frame: During treatment (week 6), post treatment (week 12), 3-months follow-up, 6-months follow-up.

  8. School absenteeism - clinician

    The assessor will evaluate school absenteeism during the past month at all assessment points. The assessor will ask the participant and the caregiver if the participant has full, partial or no school attendance (i.e., school drop-out).

    Time frame: Baseline (week 0), post treatment (week 12), 3-months follow-up, 6-months follow up.

  9. BASS platform usage data

    Usage data will be extracted from the BASS platform and entered into the trial database. These data are collected manually for each participant, including number of logins, number of messages sent to the therapist, and the name of the therapist.

    Time frame: Post treatment (week 12), 3-months follow-up.

  10. Therapist time

    The therapist time spent on each participant will be logged.

    Time frame: Post treatment (week 12).

  11. Completed modules

    Descriptive statistics on the proportion of individuals in each group having completed at least 4 modules will be reported.

    Time frame: Post treatment (week 12).

07

Study locations

3 of 3 sites recruiting
  • Forskningsmottagning barn- och ungdomspsykiatri Lund
    Lund, Skåne County 222 41, Sweden
    Recruiting
  • BUP Specialmottagning
    Gothenburg, Västra Götalandsregionen 411 14, Sweden
    Recruiting
  • Child and Adolescent Psychiatry Research Center
    Stockholm, 113 30, Sweden
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2028, 49 months after the start.

Of 235 non-industry interventional studies with no phase under Obsessive-Compulsive Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 63. This study's planned 49 months is above that.

Counting every sponsor, half of 238 studies reached it within 43 months; a quarter within 22 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2024
First posted
Sep 3, 2024
StartActual
Nov 25, 2024
Primary completionEst.
Dec 2028
CompletionEst.
Mar 2029
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06582225
Responsible party
David Mataix-Cols (Principal Investigator, Karolinska Institutet) — Principal investigator
First posted
Sep 3, 2024
Start date
Nov 25, 2024
Primary completion
Dec 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Sep 14, 2026

Study contacts

David Mataix-Cols
Contact
david.mataix.cols@ki.se
+46723986889
Moa Warnström
Contact
moa.warnstrom@ki.se
+46768419808
David Mataix-Cols
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion